Newron's Plunge Deepens as FDA Pause Hits Evenamide; Conferences Offer No Immediate Catalyst
03.06.2026 - 16:44:18 | boerse-global.de
Newron Pharmaceuticals is sending its top brass to investor conferences in June, but the roadshow arrives with no fresh clinical data to counter a regulatory overhang that has already lopped nearly half the company's market value since the start of the year. CEO Stefan Weber and CFO Roberto Galli will step onto the stage at the Jefferies Global Healthcare Conference in New York on June 4, followed later in the month by the H.C. Wainwright Neuro Perspectives Conference. What investors are hoping for, however, is not a polished presentation but a concrete update on the FDA's clinical hold that has upended the company's lead program.
The hold was disclosed in an April ad hoc announcement, triggered by the sudden death of a trial participant at a non-U.S. site. The investigator deemed the event unrelated to treatment, and an independent data safety monitoring board recommended that both studies continue as planned. Still, the FDA halted enrollment of new patients at U.S. sites of the ENIGMA-TRS 2 study — a blockade that remains unresolved. Newron says it is working with the agency to deliver the requested information and lift the stop, but no timeline has been given.
The stock price reflects the uncertainty. On Wednesday, shares changed hands at EUR 13.45 on Xetra, where trading was exceptionally thin — just 118 shares had traded by midday. The lack of liquidity amplifies the downside: a single sell order can move the price disproportionately. Interestingly, the order book shows more buyers than sellers, with roughly 29,000 shares on the bid side against 20,000 on the offer. Yet the pressure persists, a sign of how little depth the market offers.
Should investors sell immediately? Or is it worth buying Newron SpA?
From its 52-week high of EUR 34.15, reached in January, the stock has fallen more than 60%. The 200-day moving average of around EUR 18 sits more than 26% above current levels, underscoring the breadth of the retreat. Since the start of 2025, the decline stands at roughly 50%.
At the heart of the story is Evenamide, a first-in-class glutamate modulator in a global Phase III program for treatment-resistant schizophrenia. ENIGMA-TRS 1 continues to enroll and has already passed the 400-patient mark. ENIGMA-TRS 2 holds regulatory approvals in Argentina and India, with authorizations in Colombia and Malaysia nearing completion. Newron has stressed that prior clinical data show efficacy in the target population and a favorable safety profile.
Financially, the company is not in immediate distress. A capital increase agreement provides access to up to EUR 38 million. License income from 2025 adds EUR 8.6 million, and royalty payments from the Parkinson's drug Xadago, via partner Zambon, contribute roughly EUR 7.8 million. These cushions give Newron some runway, but the market's focus remains on the FDA hurdle.
The upcoming conferences present an opportunity for management to address investor concerns directly. A live presentation at Jefferies is planned, alongside one-on-one meetings, while the H.C. Wainwright event will feature a pre-recorded talk available on demand. Whether these appearances can stabilize the share price will depend entirely on whether Weber and Galli can signal progress in the FDA dialogue. Without a formal lifting of the clinical hold, the stock is likely to remain under pressure — and the conference circuit, for now, offers talk, not a catalyst.
Ad
Newron SpA Stock: New Analysis - 3 June
Fresh Newron SpA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
